Dr Anne Peters discusses updates in the ADA 2026 Standards of Care in Diabetes, focusing on the use of technology.

The company is hiring sales reps and transitioning staff from its former partner to support launches in Germany, Italy, Spain and Sweden.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

In patients with type 1 diabetes, use of continuous glucose monitoring (CGM) devices -- alone or with insulin pumps -- was associated with lower odds of developing diabetic retinopathy and ...

Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients using a lancet ...

Senseonics Holdings, Inc. SENS recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its ...

Senseonics is bringing the commercialization and distribution of its continuous glucose monitor products back in-house. The Germantown, MD-based company said it has signed a Memorandum of ...

Continuous glucose monitoring (CGM) technology, while very early in its development, has been optimistically extolled in numerous editorial and technical reviews in the medical literature as “the ...

Medical device maker Medtronic has teamed up with Fitbit to integrate physical activity data with blood glucose levels into one streamlined application. People living with type 2 diabetes who use ...

Apple Watch now supports glucose monitoring via CGMs like Dexcom G7, while Apple continues long-term work on non-invasive blood sugar tracking.

The initiative aims to move beyond single-parameter glucose tracking by integrating key cardio-metabolic biomarkers directly ...

The medical device specialist lagged the market, and even with a bit of a rebound toward the second half of 2025, shares are ...